1203 related articles for article (PubMed ID: 28462699)
1. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
2. [Optimization of Formulation and Process of Paclitaxel PEGylated Liposomes by Box-Behnken Response Surface Methodology].
Shi YJ; Zhang XF; Guo QT
Zhong Yao Cai; 2015 Dec; 38(12):2606-10. PubMed ID: 27352544
[TBL] [Abstract][Full Text] [Related]
3. Meloxicam-loaded Phospholipid/solutol® HS15 Based Mixed Nanomicelles: Preparation, Characterization, and in vitro Antioxidant Activity.
Shaji J; Varkey D
Pharm Nanotechnol; 2016; 4(3):167-190. PubMed ID: 29052497
[TBL] [Abstract][Full Text] [Related]
4. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K
J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340
[TBL] [Abstract][Full Text] [Related]
5. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design.
Vali AM; Toliyat T; Shafaghi B; Dadashzadeh S
Drug Dev Ind Pharm; 2008 Jan; 34(1):10-23. PubMed ID: 18214751
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
[TBL] [Abstract][Full Text] [Related]
7. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam.
Khurana S; Jain NK; Bedi PM
Life Sci; 2013 Nov; 93(21):763-72. PubMed ID: 24113071
[TBL] [Abstract][Full Text] [Related]
9. Meloxicam encapsulated nanostructured colloidal self-assembly for evaluating antitumor and anti-inflammatory efficacy in 3D printed scaffolds.
Rarokar N; C R; Gurav S; Khedekar P
J Biomed Mater Res A; 2021 Aug; 109(8):1441-1456. PubMed ID: 33289225
[TBL] [Abstract][Full Text] [Related]
10. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
Gandhi R; Khatri N; Baradia D; Vhora I; Misra A
Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675
[TBL] [Abstract][Full Text] [Related]
11. Optimization of prednisolone-loaded long-circulating liposomes via application of Quality by Design (QbD) approach.
Sylvester B; Porfire A; Muntean DM; Vlase L; Lupuţ L; Licarete E; Sesarman A; Alupei MC; Banciu M; Achim M; Tomuţă I
J Liposome Res; 2018 Mar; 28(1):49-61. PubMed ID: 27788618
[TBL] [Abstract][Full Text] [Related]
12. Development of risperidone liposomes for brain targeting through intranasal route.
Narayan R; Singh M; Ranjan O; Nayak Y; Garg S; Shavi GV; Nayak UY
Life Sci; 2016 Oct; 163():38-45. PubMed ID: 27593571
[TBL] [Abstract][Full Text] [Related]
13.
Dhande R; Tyagi A; Sharma RK; Thakkar H
Pulm Pharmacol Ther; 2018 Apr; 49():36-45. PubMed ID: 29337265
[TBL] [Abstract][Full Text] [Related]
14. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy.
Ghafari M; Haghiralsadat F; Khanamani Falahati-Pour S; Zavar Reza J
J Cell Biochem; 2020 Jul; 121(7):3584-3592. PubMed ID: 31907989
[TBL] [Abstract][Full Text] [Related]
16. Elastic liposomes bearing meloxicam-beta-cyclodextrin for transdermal delivery.
Jain SK; Gupta Y; Jain A; Amin S
Curr Drug Deliv; 2008 Jul; 5(3):207-14. PubMed ID: 18673264
[TBL] [Abstract][Full Text] [Related]
17. QbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC Treatment.
Shinde A; Panchal K; Patra P; Singh S; Enakolla S; Paliwal R; Chaurasiya A
AAPS PharmSciTech; 2024 May; 25(5):97. PubMed ID: 38710894
[TBL] [Abstract][Full Text] [Related]
18. Drug-fortified liposomes as carriers for sustained release of NSAIDs: The concept and its validation in the animal model for the treatment of arthritis.
Pawar VA; Manjappa AS; Murumkar PR; Gajaria TK; Devkar RV; Mishra AK; Yadav MR
Eur J Pharm Sci; 2018 Dec; 125():11-22. PubMed ID: 30219410
[TBL] [Abstract][Full Text] [Related]
19. The Evaluation of Meloxicam Nanocrystals by Oral Administration with Different Particle Sizes.
Yu Y; Tian Y; Zhang H; Jia Q; Chen X; Kang D; Du Y; Song S; Zheng A
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056734
[TBL] [Abstract][Full Text] [Related]
20. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
